Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 44,000 KRW
Change Today -250.00 / -0.56%
Volume 170.1K
As of 2:29 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

inbody co ltd (041830) Snapshot

Open
44,650
Previous Close
44,250
Day High
45,250
Day Low
43,900
52 Week High
07/23/15 - 55,300
52 Week Low
09/23/14 - 21,200
Market Cap
602.1B
Average Volume 10 Days
302.3K
EPS TTM
652.00
Shares Outstanding
13.7M
EX-Date
12/29/14
P/E TM
67.5x
Dividend
60.00
Dividend Yield
0.14%
Current Stock Chart for INBODY CO LTD (041830)

Related News

No related news articles were found.

inbody co ltd (041830) Related Businessweek News

No Related Businessweek News Found

inbody co ltd (041830) Details

Inbody Co., Ltd. operates in the body composition analysis industry worldwide. Its products include body composition and water analyzers under the InBody name; blood pressure monitors; and Stadiometer, a BMI measuring device, as well as Lookin’Body, a data management software. The company was formerly known as BIOSPACE Co., Ltd. The company was founded in 1996 and is headquartered in Seoul, South Korea.

Founded in 1996

inbody co ltd (041830) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

inbody co ltd (041830) Key Developments

Biospace Co., Ltd., Annual General Meeting, Mar 20, 2015

Biospace Co., Ltd., Annual General Meeting, Mar 20, 2015., at 09:00 Korea Standard Time. Location: 2 Way 54 inbadi the first floor conference room. Agenda: To approve audit reports and sales reports; to approve the dividend of cases 60 won per share cash dividend plans (excluding treasury shares 71,142 shares); and to approve director remuneration.

Biospace Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 02, 2014

Biospace Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 02, 2014., at 10:00 Korea Standard Time. Location: Gangnam-gu. Agenda: To consider about constitution (name change).

Biospace Co., Ltd., Annual General Meeting, Mar 21, 2014

Biospace Co., Ltd., Annual General Meeting, Mar 21, 2014., at 10:00 Korea Standard Time. Location: 2- way 54 dong, Gangnam-gu. Agenda: To consider audit reporting, sales reporting and external audit reports; to consider financial statements (including connections); to consider approval of the cash dividends per share of KRW 40; to consider election of Directors; to consider appointment of Auditor; to consider approval of director remuneration; and to consider other references concerning investment decisions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
041830:KS 44,000.00 KRW -250.00

041830 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 041830.
View Industry Companies
 

Industry Analysis

041830

Industry Average

Valuation 041830 Industry Range
Price/Earnings 60.9x
Price/Sales 10.9x
Price/Book 9.0x
Price/Cash Flow 56.3x
TEV/Sales 10.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INBODY CO LTD, please visit www.inbody.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.